FLULAVAL QUADRIVALENT Rx
Generic Name and Formulations:
Quadrivalent, inactivated, "split virion" influenza vaccine (types A and B); contains a total of 60mcg hemagglutinin per 0.5mL dose; formulation changes annually; susp for IM inj; contains thimerosal.
Indications for FLULAVAL QUADRIVALENT:
Adults and Children:
<6months: not established. Each dose is 0.5mL by IM inj once in the anterolateral thigh (6–11months) and in the deltoid (≥12months). 6months–8yrs (previously unvaccinated): 2 doses/season, give at least 4 weeks apart; (vaccinated in a previous season): 1 or 2 doses/season (depending on vaccination history as per annual ACIP recommendation); if 2 doses/season; give at least 4 weeks apart. ≥9yrs: 1 dose/season.
Allergy to egg protein. Life-threatening reaction to any previous flu vaccine.
Use current formulation only. Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Bleeding disorders. Immunosuppressed. Risk of sycope with injectable vaccines. Have epinephrine inj (1:1000) available. Pregnancy (Cat.B). Nursing mothers.
Concomitant vaccines: insufficient data (see full labeling). Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids): may get suboptimal response.
Local reactions (eg, pain, redness, swelling), headache, muscle aches, arthralgia, fatigue, fever, malaise; children: irritability, loss of appetite, drowsiness.
Single-dose prefilled Tip-Lok syringes (0.5mL)—10; Multi-dose vial (5mL)—1
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Romosozumab: Effective in Men With Osteoporosis
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Placebo Effect of Various Female Sexual Dysfunction Drug Txs Assessed
- Link Between Oral Diabetes Medications and Bullous Pemphigoid
- Calcium Channel Blocker May Benefit Patients With Type 1 Diabetes
- β-Cell Function in Youth With Impaired Glucose Tolerance, T2D